Discovery of maleimide derivatives as m6A demethylase ALKBH5 inhibitors
- 27 January 2025
- journal article
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 120, 118083
Abstract
No abstract availableKeywords
Funding Information
- Jiangsu Province Natural Science Foundation
- National Natural Science Foundation of China
- Fundamental Research Funds for the Central Universities
This publication has 24 references indexed in Scilit:
- A LATS2 and ALKBH5 positive feedback loop supports their oncogenic rolesCell Reports, 2024
- Rational Design and Optimization of m6A-RNA Demethylase FTO Inhibitors as Anticancer AgentsJournal of Medicinal Chemistry, 2022
- Detailed resume of RNA m6A demethylasesActa Pharmaceutica Sinica B, 2022
- A novel inhibitor of N6-methyladenosine demethylase FTO induces mRNA methylation and shows anti-cancer activitiesActa Pharmaceutica Sinica B, 2021
- Leukemogenic Chromatin Alterations Promote AML Leukemia Stem Cells via a KDM4C-ALKBH5-AXL Signaling AxisCell Stem Cell, 2020
- Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune EvasionCancer Cell, 2020
- Recent developments of small molecules targeting RNA m6A modulatorsEuropean Journal of Medicinal Chemistry, 2020
- RNA Demethylase ALKBH5 Selectively Promotes Tumorigenesis and Cancer Stem Cell Self-Renewal in Acute Myeloid LeukemiaCell Stem Cell, 2020
- Small-Molecule Targeting of Oncogenic FTO Demethylase in Acute Myeloid LeukemiaCancer Cell, 2019
- The formation of internal 6-methyladenine residues in eucaryotic messenger rnaInternational Journal of Biochemistry, 1992